drugset

drugset / Trial / NCT00523913

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes

NCT00523913 ↗

Phase 3 Completed 70 enrolled GlaxoSmithKline

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is designed to evaluate the safety of BRL49653C administrated for 52 weeks

Timeline

Start: 2005-11
Primary completion: —
Completion: 2007-04

Publications

Background This study has not been published in the scientific literature.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rosiglitazone	Small molecule	—	—

Indications